Title : Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.

Pub. Date : 2005 Jul

PMID : 16422846






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. Nitrates phosphodiesterase 5A Homo sapiens
2 Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. Nitrates phosphodiesterase 5A Homo sapiens
3 Phosphodiesterase type 5 (PDE5) inhibitors are effective in up to 80% of men but are contraindicated in the presence of oral nitrates, because of a potentially severe hypotensive interaction. Nitrates phosphodiesterase 5A Homo sapiens
4 MAIN OUTCOME MEASURES: Discontinuation of oral nitrates to facilitate subsequent use of PDE5 therapy. Nitrates phosphodiesterase 5A Homo sapiens
5 Forty-nine of the 52 men no longer taking nitrates were treated with a PDE5 inhibitor which was effective in 22 out of 26 (85%) patients who have completed follow-up. Nitrates phosphodiesterase 5A Homo sapiens
6 CONCLUSION: Oral nitrates can be discontinued in the presence of continuing beta-blockade and/or calcium antagonist therapy in stable coronary disease patients with ED to allow for the safe use of PDE5 inhibitors. Nitrates phosphodiesterase 5A Homo sapiens